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Abstract
Elevated levels of p130Cas/BCAR1 (Crk-associated substrate/breast cancer antiestrogen resistance 1) are found in
aggressive breast tumors and are associated with tamoxifen resistance of mammary cancers. p130Cas promotes the
integration of protein complexes involved in multiple signaling pathways frequently deregulated in breast cancer. To
elucidate mechanisms leading to p130Cas up-regulation in mammary carcinomas and during acquired tamoxifen
resistance, the regulation of p130Cas/BCAR1 was studied. Because multiple putative binding motifs for the inducible
transcription factor EGR1 were identified in the 5′ region of BCAR1, the p130Cas/BCAR1 regulation by EGR1 and its
coregulator NAB2 was investigated. Overexpression or short interfering RNA (siRNA)–mediated down-regulation of
EGR1 or NAB2, and chromatin immunoprecipitations indicated that EGR1 and NAB2 act in concert to positively reg-
ulate p130Cas/BCAR1 expression in breast cancer cells. p130Cas depletion using siRNA showed that, in tamoxifen-
sensitive MCF-7 cells, p130Cas regulates EGR1 and NAB2 expression, whereas in the derivative tamoxifen-resistant
TAM-R cells, only NAB2 levels were influenced. BCAR1 messenger RNA and p130Cas protein were upregulated by
phorbol esters following the kinetics of late response genes in MCF-7 but not in TAM-R cells. Thus, in MCF-7 cells,
we identified a positive feedback loop where p130Cas positively regulates EGR1 and NAB2, which in turn induce
p130Cas expression. Importantly, compared with MCF-7, enhanced NAB2 expression and increased EGR1 binding
to the BCAR1 5′ region observed in TAM-R may lead to the constitutively increased p130Cas/BCAR1 levels in TAM-R
cells. The uncovered differences in this EGR1/NAB2/p130Cas network in MCF-7 versus TAM-R cells may also contribute
to p130Cas up-regulation during acquired tamoxifen resistance.
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Introduction
p130 Crk-associated substrate (p130Cas) is an adapter protein that
was first isolated from v-Src– and v-Crk–transformed rat fibroblasts
[1]. Its gene was independently identified as breast cancer antiestrogen
resistance 1 (BCAR1) [2,3]. Here, we refer to the gene and messenger
RNA (mRNA) as BCAR1 and to the protein as p130Cas. p130Cas is the
founding member of the Cas family, which includes HEF1 (NEDD9),
Efs/Sin, and HEF1-Efs-p130Cas-Like (HEPL) [4–6]. Proteins of this
family function as scaffolds integrating large multiprotein complexes
in response to stimuli, such as growth factor and hormone release,
and integrin engagement [5,7–9]. Evidence shows that signaling path-
ways activated by several of these stimuli are frequently enhanced in
breast cancer, for example, by overexpression of receptor tyrosine
kinases (RTKs) of the ErbB family (ErbB1 [EGF receptor] and ErbB2
[Her2/neu]) [10,11], integrin receptors (α3β1 and αvβ3 integrins)
[8,12], and estrogen [13].
Abbreviations: BCAR1, breast cancer antiestrogen resistance 1; ChIP, chromatin immu-
noprecipitation; p130Cas, Crk-associated substrate; dn, dominant negative; EGR, early
growth response; ev, empty vector; ER, estrogen receptor; ERE, estrogen response ele-
ment; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HIF, hypoxia-inducible
factor; NAB2, NGFI-A binding protein 2; PPIA, peptidylprolyl isomerase A; PI3K,
phosphatidylinositol 3-kinase; RT-PCR, reverse transcription–polymerase chain reaction;
RPLP0, ribosomal protein, large, P0; RN18S1, RNA 18S ribosomal 1; siRNA, short
interfering RNA; TF, transcription factor; TSS, transcription start site; WB,Western blot
analysis; WCE, whole cell extract; wt, wild-type
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In breast cancer patients, elevated p130Cas levels are associated with
an increased rate of relapse and aggressiveness of the disease [14].
p130Cas expression is higher in pleural effusions of breast cancer
patients compared with primary tumors [15]. Also, in feline and
canine models of breast cancer, p130Cas levels positively correlate with
advanced breast carcinomas [16]. Increased p130Cas protein expres-
sion has been implicated in mediating resistance to Adriamycin and
tamoxifen [17,18]. Recent in vitro studies have shown elevated
p130Cas levels in tamoxifen-resistant breast cancer cells (TAM-R) that
were derived from tamoxifen-sensitive MCF-7 cells [19]. Resistance
to antiestrogens such as tamoxifen and fulvestrant has also been
associated with enhanced growth factor signaling involving the up-
regulation of RTKs of the ErbB family and augmented Akt pathway
activation [19–21]. Disruption of the p130Cas signaling node leads to
attenuation of the extracellular signal–regulated kinase (ERK) and
phosphatidylinositol 3-kinase (PI3K)/Akt survival pathways, reduced
migration, and resensitization of TAM-R cells to tamoxifen [19].
Members of the early growth response (EGR) transcription factor
(TF) family have been implicated in breast cancer progression and
antiestrogen resistance [22,23]. The zinc finger factors EGR1
(NGFI-A), EGR2 (Krox-20), and EGR3 are immediate early response
genes that are important for the regulation of differentiation, prolifer-
ation, and cell death in response to environmental stimuli [24,25].
Extracellular signals such as cytokines, growth factors, and hormones
that lead to the activation/phosphorylation of p130Cas also rapidly
and transiently induce the expression of the EGR family members
[26,27]. EGR target genes comprise, for example, vascular endothelial
growth factor (VEGF) [28], PDGF [29], as well as cyclin-dependent
kinase 1 inhibitor p21Waf1/Cip1 [22]. The activity of the EGRTFs is mod-
ulated in part through the gene product of its own target, the delayed
early response gene NGFI-A binding protein 2 (NAB2) [30–32].
Given the number of studies that link p130Cas levels to breast cancer
progression and the fact that tamoxifen is still a commonly used drug in
hormonal adjuvant therapy, understanding the p130Cas gene regulation
in mammary carcinomas is of great importance. However, the regula-
tory mechanisms that upregulate p130Cas expression in mammary car-
cinomas and during acquired tamoxifen resistance in human breast
tumors are elusive. Here, we demonstrate the presence of two BCAR1
mRNAs, using alternative first exons, in normal human mammary
gland tissue and in breast tumors. The results suggest that, in breast
cancer cells, p130Cas expression/signaling upregulates the TF EGR1 and
its coregulator NAB2, which, in turn, are involved in the induction of
p130Cas expression. This regulatory network was altered in tamoxifen-
resistant breast cancer cells, which exhibited higher NAB2 levels. There-
fore, our studies identified a transcriptional circuit that controls p130Cas
expression in breast cancer cells and a p130Cas-controlled regulatory net-
work that may contribute to acquired tamoxifen resistance.
Materials and Methods
Cell Lines and Culture Conditions
Cell lines were purchased from the American Type Culture Collec-
tion (ATCC, Manassas, VA) or obtained as indicated. The following
cell lines were used: BT-20 (Sam Lee, Massachusetts General Hospital;
human breast carcinoma, estrogen receptor [ER] negative); ZR-75-1,
MCF-7, and the MCF-7–derivative TAM-R (Robert Nicholson, Cardiff,
United Kingdom; human breast carcinoma, ER positive). MCF-7 cells
were grown in RPMI-1640 supplemented with 10% fetal bovine serum
(FBS), 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicil-
lin, and 100 U/ml streptomycin. TAM-R cells were cultured in phenol
red–free RPMI-1640 and 10% charcoal-stripped FBS, supplemented
with 4 mM glutamine and antibiotics/sodium pyruvate as previously
mentioned. BT-20 and ZR-75-1 cells were cultured in Dulbecco mod-
ified Eagle medium, 10% FBS, and supplemented as previously men-
tioned. Cells were maintained at 37°C and 5% CO2 and tested for
Mycoplasma contamination.
For phorbol myristate acetate (PMA) treatment, 2 × 105 cells were
seeded in six-well plates and, after 24 hours of plating, serum starved
(0.5% serum) for 16 hours before stimulation by the addition of PMA
(final concentration 10 ng/ml; Sigma, St Louis, MO) for indicated times.
Generation of Expression Constructs
Human wild-type (wt) and dominant negative (dn) NAB2 comple-
mentary DNAs (cDNA) [32,33] were subcloned into pCXbsr digested
with BamHI. Human EGR1 cDNA was obtained by reverse tran-
scription (RT) of total RNA prepared from MCF-7 cells stimulated
for 2 hours with PMA using the EGR1-specific reverse primer EGR1-
NotI, including a NotI site (Table 1, for primer sequences). The ob-
tained EGR1 cDNA was amplified by polymerase chain reaction
(PCR) using Pfu polymerase with the EGR1–EcoRI forward primer
and the EGR1–NotI reverse primer and subcloned into the EcoRI/
NotI–digested pCXbsr vector. Constructs were validated by sequenc-
ing. QIAGEN Plasmid Maxi Kit (Qiagen, Valencia, CA) was used for
DNA preparation.
Table 1. Primer Sequences.
Name Forward (5′–3′) Name Reverse (5′–3′)
EGR1-EcoRI ATAGAATTCATGGCCGCGGCCAAGGCCG EGR1-NotI ATAGCGGCCGCTTAGCAAATTTCAATTGTCCTGG
BCAR1 total TGGAGCAGGACACGCAGGG BCAR1-rev GGTGGGCACCACCACCTTTG
BCAR1-1 CGGACACCATGAACCACCTGAA
BCAR1-1′ CCAAGATGTCCGTGCCTAAC
BCAR1-1q GACACCATGAACCACCTGAA BCAR1q-rev TCATACATGCCCACCAAGAT
BCAR1-1′q CGGCCAAGATGTCCGTGC
BCAR1 totalq-f GTCCACCTACAGGGGAAGGA BCAR1 totalq-rev CGTGACACCTCCTGTTCCAG
GAPDHq-f TGCACCACCAACTGCTTAGC GAPDHq-r GGCATGGACTGTGGTCATGAG
PPIAq-f TTGGGCCAATAAGAAGTTGTGAA PPIAq-r AACCGACTGGCTAAAATCCAC
RPLP0q-f GCTGCTGCCCGTGCTGGTG RPLP0q-r TGGTGCCCCTGGAGATTTTAGTGG
RN18S1q-f CGGCTACCACATCCAAGGAA RN18S1q-r TTTTCGTCACTACCTCCCCG
BCAR1-1 −226 CTCGGGCAGGGGCCTGGAG BCAR1-1 −58 AGCCCGATCCCAGCATGC
BCAR1_1′ −360 TCCTCTTCCCTGGGGGTCTC BCAR1-1′ −162 TCTGGGTCGCCCAACCAGTC
control-f ATGGTTGCCACTGGGGATCT control-r TGCCAAAGCCTAGGGGAAGA
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In Silico Analysis
Analyses of BCAR1 and the exon 1 mRNA and protein variants
were conducted using database resources and software from AceView
[34], the EMBL–European Bioinformatics Institute, Genomatix [35],
and the National Center for Biotechnology Information. In silico anal-
ysis of putative promoter regions was performed using the Genomatix
suite of programs.
Retroviral Transduction
Retroviral transduction was carried out as described [19,36]. Briefly,
transient expression of EGR1, wt or dn NAB2, and/or empty vector (ev)
control in MCF-7, TAM-R, and BT-20 cells was achieved by transduc-
tion with equal volumes of supernatant containing amphotropic CXbsr
virus particles that carry either the cDNAs for EGR1, wt or dn NAB2,
or ev. Equal amounts of ev control supernatant were added to the single-
gene transductions to control for DNA amounts/virus titer. To enrich for
cells expressing the introduced cDNAs, cells were selected with 10 μg/ml
Blasticidin (Invitrogen, Grand Island, NY) for 3 days before harvesting.
RNA Interference
Transfection of p130Cas short-interfering RNAs (siRNAs) was per-
formed as previously described [19]. Depletion of human EGR1 was
achieved by transfection of pooled siRNA (50 nM) in 12-well plates
after 38 hours using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s recommendations. ON-TARGETplus SMART
pool siRNA targeting EGR1 (catalog no. L-006526-00-0005) and neg-
ative control (catalog no. D-001810-01-05) were purchased from
Dharmacon (Chicago, IL). Sequences of siRNA-specific for EGR1were
as follows: 5′-GAUGAACGCAAGAGGCAUA-3′; 5′-CGACAGCA-
GUCCCAUUUAC-3′; 5′-GGACAUGACAGCAACCUUU-3′; 5′-
GACCUGAAGGCCCUCAAUA-3′. Down-regulation of human
NAB2 was achieved by transfection of pooled siRNAs (50 nM) in
12-well plates after 72 hours using Lipofectamine 2000. siRNA
sequences targeting NAB2 (catalog no. sc-36014; Santa Cruz Bio-
technology, Santa Cruz, CA) were as follows: 5′-CCAACCUC-
CUUUCCUACUAtt-3′; 5′-CAACCUCCUUUCCUACUAUtt-3′;
5′-CCUACUUGUCCUCCUUGAAtt-3′.
Protein Analysis
Whole cell extracts (WCEs) were prepared and analyzed by West-
ern blot analysis (WB) as described [37]. Briefly, cells were incubated
in HNTG lysis buffer (50 mM HEPES [pH 7.4], 150 mM NaCl,
1% Triton X-100, 10% glycerol, 10 mM EDTA) supplemented with
protease inhibitor cocktail (Roche, Nutley, NJ) and phosphatase
inhibitors (1 mM sodium vanadate and 1 mM sodium fluoride) for
30 minutes on ice followed by centrifugation at 16,000g and 4°C for
30 minutes. Equal amounts of protein were analyzed by SDS-PAGE.
Antibodies (Abs) used were mAbs against β-actin (Sigma), NAB2 [38],
and p130Cas (clone 21; BD Transduction Laboratories, Sparks, MD).
Polyclonal rabbit Abs against EGR1 (588; sc-110) were purchased
from Santa Cruz Biotechnology.
Reverse Transcription–PCR
Cells were washed twice with cold PBS and RNA was extracted
using TRIzol reagent (Invitrogen). Total RNA (2 μg) was reverse
transcribed using SuperScript II Reverse Transcriptase (Invitrogen)
and random hexamer primers (Invitrogen) according to the manufac-
turer’s recommendations. cDNAs reverse transcribed using oligo-dT
primer from human breast tissue mRNA were purchased from Bio-
chain Institute (Hayward, CA). PCR was performed using 0.5 μl of
undiluted cDNA in a 20-μl PCR with the use of Taq DNA polymer-
ase and reaction buffer from Biochain Institute. To check for linear
amplification, each PCR was performed at different cycle numbers.
Exon overlapping PCR primers were applied to exclude amplification
of genomic DNA and cDNA generated from unspliced precursor
mRNA. Primer sequences are found in Table 1. Reverse primer
BCAR1-rev was used for BCAR1 total, BCAR1-1, and BCAR1-1′
amplifications. Forward primers and amplicon sizes were as follows:
BCAR1 total, 551 bp; BCAR1-1, 657 bp; BCAR1-1′, 653 bp. Reac-
tion conditions (annealing temperature and cycle number) were as
follows: BCAR1 total, 62°C and 25; BCAR1-1, 64°C and 27; and
BCAR1-1′, 64°C and 27. The BCAR1 total reaction amplifies parts
of exon 2 and exon 3, which are present in both exon 1 variants. To
control for the integrity and uniformity of the sample preparations,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was ampli-
fied as described previously [33]. Products were separated by electro-
phoresis through 1.2% agarose gels and validated by sequencing.
Quantification of Gel Bands
Densitometric analysis of gel bands was performed using Quantity
One software (Bio-Rad). Equal adjustments of contrast and bright-
ness of gel pictures and scanned films were applied to all parts of
the image using Adobe Photoshop CS2 version 9.0. Vertical lines in
Figures 1D, 3, 4A and B, and 8A indicate that results from different
WB are shown.
Real-time PCR
Real-time PCR was performed in 20-μl reactions in triplicate
using ABI PRISM 7300 Sequence Detection System Version 1.4.0
(Applied Biosystems, Carlsbad, CA) and 2× FastStart Universal SYBR
Green PCRMaster (ROX; Roche Applied Science, Indianapolis, IN) as
recommended by the manufacturer using 2 ng of cDNA, reverse tran-
scribed as described previously. Comparative C t method was applied
for relative quantification of each gene expression between samples
[39] and normalized to GAPDH, peptidylprolyl isomerase A (PPIA),
ribosomal protein, large, P0 (RPLP0), and RNA 18S ribosomal 1
(RN18S1) levels, as indicated. PCR specificity and amplicon size were
validated by electrophoresis through a 2% agarose gel and subsequent
sequencing. Efficiency of each PCR was more than 98% as determined
by performing the PCRs for each primer pair with serial DNA dilu-
tions. Primer sequences are presented in Table 1. Reverse primer
BCAR1q-rev was used for BCAR1-1 and BCAR1-1′ amplifications.
Forward primers and amplicon sizes were as follows: BCAR1-1q,
209 bp; BCAR1-1′q, 211 bp. BCAR1 total levels were detected by am-
plification of a region from exon 5 to exon 7, which is present in both
exon 1 variants, using the primers BCAR1 totalq-f and BCAR1 totalq-rev.
Primers used inGAPDH, PPIA,RPLP0, andRN18S1 PCRs are shown
in Table 1. Primers for EGR1 andNAB2 were described previously [33].
Chromatin Immunoprecipitation Real-time PCR
Briefly, 2.5 × 106 (MCF-7) or 3 × 106 (TAM-R) cells were seeded in
10-cm dishes and after 1 day of plating serum starved (0.5% serum) for
16 hours before harvesting. Subsequently, chromatin immunoprecipi-
tation (ChIP) was performed using EZ-ChIP kit (Millipore, Billerica,
MA) following the manufacturer’s protocol using 4 μg of antibody.
Abs used were as follows: rabbit anti-EGR1 (588, sc-110; Santa Cruz
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Biotechnology) and normal rabbit IgG control (sc-2027; Santa Cruz
Biotechnology). ChIP real-time PCRs were performed as described pre-
viously using 3 μl of purified DNA. For amplification of the BCAR1-1
and BCAR1-1′ 5′ regions, 4 μl of 5 M betaine (Sigma) was added to the
PCRs. Primers (for sequences, see Table 1) and amplicon sizes were as
follows: BCAR1-1 −226 and BCAR1-1 −58, 169 bp; BCAR1-1′ −360
and BCAR1-1′ −162, 199 bp. As control for chromatin bound nonspe-
cifically, a human negative control primer set (control-f and control-r;
amplicon size, 174 bp; Active Motif, Carlsbad, CA) was used. Specific-
ity of the PCRs was validated by electrophoresis through 1.6% agarose
gels and subsequent sequencing. The enrichment of EGR1 to the ge-
nomic BCAR1 5′ or negative control regions was calculated as followed.
The percentage of the input DNA (1% of the nuclear extract used) that
was recovered was calculated for each sample, and the EGR1 values
were related to the percentage computed for the rabbit IgG control.
Subsequently, the resulting fold of IgG values obtained by the EGR1-
ChIP for the BCAR1 5′ regions were divided by the fold of IgG re-
trieved by the EGR1-ChIP for the genomic negative control region
to account for possible unspecific precipitation of genomic DNA by
the EGR1 antibody in different samples/cell lines.
Results
BCAR1—Alternative First Exon Usage in Normal and
Cancerous Breast Tissues
Recent studies have shown elevated p130Cas protein levels in
tamoxifen-resistant breast cancer cells [19] and, more importantly,
in antiestrogen-resistant breast cancers in patients [40]. Since to date
the regulation of p130Cas/BCAR1 expression remains enigmatic, a
comprehensive analysis of the BCAR1 gene was performed to decipher
mechanisms that may contribute to the observed up-regulation of
p130Cas expression.
Database searches and gene structure analysis revealed that the human
BCAR1 gene uses an alternative first exon (BCAR1-1′, NM_001170718)
located 14,402 bp upstream of the first described exon 1 (BCAR1-1,
RefSeq NM_014567.3) (Figure 1, A and B). Comparative genomics
indicated that BCAR1-1 and BCAR1-1′ reflect the p130Cas isoforms
Casa and Casb described in mice, respectively [41]. Both first exons
encode for only three distinct amino acids (aa) (NHL [BCAR1-1] and
SVP [BCAR1-1′]) and the resulting isoforms are conserved in mammals.
The genomic distance between the two first exons points to the use of
alternative promoters.
To study the regulation of BCAR1 in mammary carcinomas, we
examined the expression of BCAR1 exon 1 variant mRNA in two normal
Figure 1. BCAR1 uses alternative first exons in normal and cancer-
ous breast tissues. (A) Comparison of the human and mouse
BCAR1 genes. The human BCAR1-1 and BCAR1-1′ reflect the
murine p130Cas isoforms Casa and Casb, respectively. Boxes rep-
resent exons. // indicates that sequences of exons 3 through 6
were omitted. Numbering indicates the TSS of variant 1′ relative
to exon 1 TSS (+1). (B) Schematic of the BCAR1 Exon 1 mRNA
variants. Relative position of the translation start site (AUG) for
each variant is indicated. Black boxes indicate untranslated regions;
gray boxes, translated regions; dashed lines, spliced-out intron re-
gion. (C) Levels of BCAR1-1, BCAR1-1′, and GAPDH (control) mRNA
in human breast tissues and ZR-75-1, MCF-7 (tamoxifen-sensitive),
and TAM-R (tamoxifen-resistant) mammary carcinoma cell lines
were determined by RT-PCR as described previously. + control, pos-
itive control for PCR; − DNA, negative control for PCR. Results are
from one representative experiment of two performed. (D) Ex-
pression of BCAR1 mRNAs is increased in tamoxifen-resistant
TAM-R cells. Tamoxifen-sensitive MCF-7 and its derivative tamoxifen-
resistant TAM-R cells were cultured similarly for 2 weeks and seeded
at 3× 105 cells in six-well plates. After 3 days at a confluence of 70%
to 90%, cells were harvested and mRNA was prepared and reverse
transcribed as described previously. Levels of BCAR1-1, BCAR1-1′,
total BCAR1, and the internal controls GAPDH, PPIA, and RPLP0
mRNA in MCF-7 cells and TAM-R were determined by real-time
PCR as described previously. Shown are the results after nor-
malization to GAPDH. Similar results were obtained after normaliza-
tion to PPIA and RPLP0. Average levels relative to the expression
in MCF-7 cells (black bar, set to 1) and SD from triplicate were de-
termined as described previously. P values were calculated using
t test. *P < .05. **P < .01. Results are from one representative
experiment of two performed.
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human breast tissues, a human primary tumor, and in the human
breast cancer cell line ZR-75-1 (Figure 1C). Furthermore, to elucidate
differences in acquired tamoxifen resistance, the tamoxifen-sensitive
MCF-7 breast cancer cells and its resistant derivative, TAM-R, expres-
sing higher p130Cas protein levels [19], were used as a model system
and therefore also included. In all samples, both BCAR1 variants were
detected. Compared with normal breast tissue 1, the levels of BCAR1-1
as well as of BCAR1-1′ were increased in the primary tumor sample,
which was derived from the same donor. Higher levels of BCAR1-1′
over BCAR1-1 or vice versa were found in normal breast tissue 2 and
ZR-75-1 cells, respectively, suggesting a distinct regulation of each
BCAR1/p130Cas variant. In MCF-7 and TAM-R cells, a similar expres-
sion of both variants was detected. However, a slight increase in both
BCAR1 variants was observed in TAM-R versus MCF-7 cells.
To further investigate whether the enhanced protein levels in
TAM-R cells correlate with higher mRNA expression, BCAR1-1,
BCAR1-1′, and total BCAR1 (determined by amplification of a re-
gion spanning exons 5 to 7) mRNA expression levels were analyzed
by real-time PCR in MCF-7 and TAM-R cells (Figure 1D). Signifi-
cant increases in BCAR1-1 (1.71-fold, P < .05), BCAR1-1′ (1.61-fold,
P < .01), and total BCAR1 (1.66-fold, P < .01) were observed in
TAM-R compared to MCF-7 cells.
Taken together, these results show that BCAR1-1 and BCAR1-1′
are coexpressed in human breast tissues and breast cancer cell lines,
and both variants seem to be differentially regulated in some circum-
stances. Furthermore, tamoxifen-resistant cells have elevated mRNA
levels compared to tamoxifen sensitive.
In Silico Analysis of the Flanking Regions of the BCAR1
Exon 1 Variants Reveals Multiple Clusters of Binding
Sites for Transcription Factors of the EGR Family
To gain insight into the mechanisms regulating the p130Cas vari-
ant expression, a comprehensive phylogenetic analysis of the 5′ and
3′ flanking regions of the alternative first exons of BCAR1 was per-
formed (Figure 2).
Putative promoters colocated with CpG islands were identified in
the regions flanking human exons 1 and 1′. A CAAT box was only
found at bp −92 of exon 1 and no TATA box or initiator element is
present in both regions. The lack of these core promoter elements
points to the involvement of specific TFs in the regulation of BCAR1
expression. Owing to the elevated p130Cas levels in breast cancer
putative binding sites for TFs including members of the EGR, NF-κB,
and hypoxia-inducible factor (HIF) family, p53, AP2, estrogen response
elements (ERE), and cAMP-responsive elements binding proteins
(CREB), involved in tumor development and progression, were explored.
The region bp −800 to +400 relative to the transcription start site (TSS,
+1) of exon 1, contains 14 putative binding sites for the EGR family,
most of which overlap with nine SP1 motifs, seven p53, two AP2 sites,
and a single HIF and CREBmotif. Of note is a conserved cluster of over-
lapping binding sites (bp −196 to −125) including six EGR and five SP1
motifs. Several EGR/Sp1 motifs within bp −500 to +150 and two p53
binding sites near the CAAT box are conserved among the different
species (Figure 2).
In the 5′ region of exon 1′, an evolutionary conserved cluster of four
EGR and three overlapping SP1 sites at bp −29 to +2, one EGR1/SP1
site, and two ERE at bp +150 to +180 were predicted. In addition, nine
EGR, five SP1, four NF-κB, two HIF sites, and one ERE were iden-
tified (bp −800 to +400).
These results point to a complex regulation of the expression of the
BCAR1-1 and BCAR1-1′ variants involving members of the EGR
family and other TFs, such as NF-κB, and p53.
EGR1 and Its Coregulator NAB2 Are Involved in the
Regulation of p130Cas Expression in Human Breast
Cancer Cells
To elucidate a potential role of EGR1 and the influence of its
coregulator NAB2 on p130Cas expression, MCF-7 and TAM-R cells
were transducedwith EGR1,NAB2 (wt or dn), and ev control (Figure 3).
NAB2 is a target gene of EGR1 and, in turn, can act as corepressor
[31,32] and coactivator [30] of EGR1-mediated transcription. dnNAB2
contains an aa exchange that prevents the binding to EGR1. dnNAB2 is
still able to form complexes with endogenous NAB2, thereby greatly
abolishing the binding of also endogenous NAB2 to EGR1 [42]. Protein
levels were analyzed by WB after 5 days, which included 3 days of selec-
tion with blasticidin to enrich for cells expressing the introduced cDNAs.
Cells transduced with EGR1 had profoundly higher amounts of p130Cas
and NAB2. The influence of NAB2 on EGR1-mediated p130Cas expres-
sion was examined by cotransduction of EGR1 and NAB2. p130Cas
was not altered by coexpression of EGR1 and NAB2 compared to
EGR1 single transduction, suggesting that NAB2 does not inhibit
EGR1-mediated p130Cas expression. Cells transduced with NAB2 alone
showed also elevated p130Cas levels. Importantly, ectopic expression of
dnNAB2 did not result in higher p130Cas expression in MCF-7 and
TAM-R cells (Figure 3B). These experiments suggest that EGR1 and
NAB2 complex formation is required to increase p130Cas levels in
breast cancer cell lines.
EGR1 and NAB2 Depletion Attenuates p130Cas/BCAR1
Expression at the mRNA and Protein Levels
Subsequently, the importance of endogenous EGR1 and NAB2
in the regulation of p130Cas expression was further investigated using
siRNAs. MCF-7, TAM-R, or BT-20 breast cancer cells were trans-
fected with siRNAs directed against EGR1, NAB2, or a negative con-
trol siRNA, and the effects on p130Cas, EGR1, and NAB2 were
assessed by WB (Figure 4, A and B). Results in Figure 4A are pre-
sented for TAM-R and BT-20 cells because no adequate depletion
of EGR1 levels was achieved in MCF-7 cells. Transfection of
EGR1 siRNA resulted not only in a reduction of EGR1 levels by
70% and 41% in TAM-R and BT-20 cells, respectively, but also
of p130Cas expression by 41% (P < .01) and 50% (P < .01). NAB2
levels were also significantly (P < .01) reduced by 73% (TAM-R) and
44% (BT-20).
Depletion of NAB2 by siRNA targeting NAB2 by 63% (MCF-7)
and 74% (TAM-R) also led to a reduction of p130Cas levels (P <
.001) by 30% and 40% in MCF-7 and TAM-R cells, respectively
(Figure 4B), underscoring the importance of NAB2 in regulating
p130Cas expression. Furthermore, EGR1 expression was reduced in
TAM-R cells by 47% (P < .001), whereas in MCF-7 cells, a reduc-
tion of only 20% (P < .05) was observed.
To investigate whether endogenous EGR1 and NAB2 are involved
also in the transcriptional regulation of p130Cas expression, the
BCAR1 mRNA levels were analyzed after depletion of NAB2 by
siRNA (Figure 4C ). After NAB2 siRNA transfection, the mRNA
levels of BCAR1-1, BCAR1-1′, total BCAR1, NAB2, and EGR1 were
determined in MCF-7 and TAM-R cells by real-time PCR. Transfec-
tion of NAB2 siRNA resulted in a reduction of NAB2 levels by 49%
and 88% in MCF-7 and TAM-R cells, respectively, correlating with
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reductions in total BCAR1 expression by 56% (P < .01) and 65%
(P < .001). Corresponding to the minor effects of NAB2 depletion on
EGR1 protein levels in MCF-7 (Figure 4B), EGR1 mRNA expression
was only significantly reduced in TAM-R cells (by 78%, P < .001).
Interestingly, BCAR1-1′ levels were substantially depleted (P < .001)
by 49% (MCF-7) and 68% (TAM-R) in both cell lines, whereas
BCAR1-1 expression was reduced to a much greater extent in TAM-R
by 67% (P < .001) than in MCF-7 cells by 14% (P < .05).
Taken together, these results indicate that the TF EGR1 and its
coregulator NAB2 are positive regulators of p130Cas/BCAR1 expression
in human breast cancer cells. Importantly, NAB2 seems to be involved in
the regulation of BCAR1-1 and BCAR1-1′ expression in the tamoxifen-
resistant TAM-R cells, whereas NAB2 influences mostly BCAR1-1′
levels in the tamoxifen-sensitive MCF-7 cells.
Increased Binding of EGR1 to the BCAR1 5′ Regions
in Tamoxifen-Resistant TAM-R Compared to
Tamoxifen-Sensitive MCF-7 Cells
Because RNA interference experiments suggested that EGR1 reg-
ulates BCAR1 expression, EGR1 was tested for its ability to directly
bind to the potential BCAR1 promoter regions. ChIP assays were
performed on isolated chromatin from MCF-7 and TAM-R cells
and evaluated by real-time PCR for the genomic DNA 5′ regions of
BCAR1-1 and BCAR1-1′ that contain multiple putative EGR1 binding
Figure 2. Schematic representation of putative regulatory elements in the flanking regions of the alternative first exons of BCAR1 in
mammalian species, as indicated. Comparative genomics were performed using database resources from AceView and the Genomatix
suite of programs. Different species were used for the analysis of the BCAR1-1 and BCAR1-1′ regions owing to a restricted availability
and gaps in the genomic sequence. Predicted promoter regions, CpG islands, and TF binding sites are indicated for BCAR1-1 and
BCAR1-1′. Conserved cis regulatory elements are emphasized by gray dashed lines/blocks. Numbering is relative to TSS (+1, gray boxes);
exon 1: black boxes, untranslated regions; small white boxes, translated regions.
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sites (Figure 5A). Binding to these specific regions was investigated be-
cause they are located in the predicted promoter regions, and similar
clusters of EGR/Sp1 sites in a comparable distance from the TSS were
identified as crucial in multiple other promoters [28,29,32]. To ac-
count for nonspecific binding of EGR1, the recovery of DNA by
IgG control serum and enrichment to a genomic negative control re-
gion were included in the calculation as described in the Materials and
Methods. InMCF-7 cells, EGR1 binding was found located within the
5′ region from bp −226 to −58 of BCAR1-1 (2.9-fold enrichment, P <
.001) containing a cluster of multiple overlapping EGR/Sp1 and a
single EGR1 site, whereas no binding was detectable to the 5′ region
of BCAR1-1′ from bp −360 to −162 (Figure 5B). This region similarly
contains two clusters of overlapping EGR/Sp1 motifs. In contrast,
in TAM-R cells, binding of EGR1 to BCAR1-1 (7.96-fold enrichment,
P < .001) and BCAR1-1′ (2.53-fold enrichment, P < .05) was observed.
The binding to BCAR1-1 in TAM-R cells was significantly higher (P <
.001) than in MCF-7 cells.
These results suggest differential regulation of the p130Cas variant
expression in MCF-7 versus TAM-R cells by EGR1.
Aggressive and Late-Stage Breast Cancers Display Elevated
NAB2 Levels
As more significant effects by depletion of the EGR1 coregulator
NAB2 were observed in TAM-R versus MCF-7 cells, NAB2 expres-
sion in both cell lines was compared. MCF-7 and TAM-R cells were
cultured similarly for 2 weeks to eliminate differences in the basal
expression of EGR1 and NAB2 induced by varied culture condi-
tions. WB of basal p130Cas, EGR1, and NAB2 protein levels
(Figure 6A) showed similar EGR1 levels in both cell lines but profoundly
Figure 3. EGR1 and NAB2 are involved in the regulation of p130Cas
expression. (A and B) MCF-7 and TAM-R cells were transduced
with the indicated cDNAs for 2 days and selected for 3 days with
blasticidin as described previously. WCEs (20 μg) were separated
by SDS-PAGE, subjected to WB, and probed with the indicated
antibodies. Data are presented from one experiment of at least
three performed with similar results.
Figure 4. Endogenous EGR1 and NAB2 are important regulators of
p130Cas expression. (A) BT-20 and TAM-R cells were transfected
with siRNAs for EGR1 or control siRNA. WCEs (20 μg) were ana-
lyzed for p130Cas, EGR1, NAB2, and actin (loading control) expres-
sion by WB 38 hours after treatment (left panel). Right panel:
Densitometric analysis of protein expression. (B) MCF-7 and
TAM-R cells were transfected with siRNAs for NAB2 or control
siRNA. WCEs (20 μg) were analyzed for p130Cas, EGR1, NAB2,
and actin (loading control) expression by WB 72 hours after treat-
ment. Right panel: Densitometric analysis of protein expression.
(A and B) Average expression levels relative to negative control
(black bar, set to 100%) and SD from three representative ex-
periments performed were determined as described previously.
(C) MCF-7 and TAM-R cells were transfected with siRNAs for
NAB2 or control siRNA. After 72 hours, mRNA levels of BCAR1-1,
BCAR1-1′, total BCAR1, NAB2, EGR1, and the internal controls
RPLP0, PPIA, and RN18S1 in MCF-7 and TAM-R cells were deter-
mined by real-time PCR as described previously. Shown are the
results after normalization to RPLP0. Similar results were obtained
after normalization to PPIA and RN18S1. Average levels relative
to the expression in MCF-7 cells (black bar, set to 100%) and SD
from triplicate were determined as described previously. Results
are from one representative experiment of two performed. (A-C)
P values were calculated using t test. *P < .05. **P < .01. ***P <
.001. n.s. indicates not significant.
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elevated NAB2 levels in tamoxifen-resistant TAM-R cells. Commonly,
breast cancers with acquired tamoxifen resistance represent more ad-
vanced tumors that are difficult to treat. Therefore, we investigated
whether increasedNAB2 levels correlate with mammary carcinoma grade
and/or malignancy by analyzing microarray gene expression data sets
available at www.oncomine.org. For microarray studies to be included,
we required a minimum of five samples for each group and a similar
trend in expression differences if multiple reporters were used in these
studies. The NAB2 mRNA levels significantly increased from grade 2
to grade 3 specimens of human invasive ductal breast cancers in the
Ginestier study (P = .023, reporter number 216017_s_at) [43]
(Figure 6B, left panel). A similar increase was observed in the study of
Zhao et al. [44] (P = .033, reporter IMAGE:1926749; not shown),
whereas no significant changes from grade 2 to grade 3 were detected
in the Radvanyi study (reporter number U48361) [45] (not shown).
Thus, the analyses were extended to compare NAB2 levels in primary
sites and metastases of breast cancer patients. The levels ofNAB2mRNA
were significantly higher in metastasis versus primary site in the Radvanyi
study (P = .023, reporter number U48361) [45] (Figure 6B, right panel).
Similar results were found in two other microarray studies (not shown)
that fulfilled our requirements, supporting these findings. These data sug-
gest that advanced human breast cancers express higher levels of NAB2.
p130Cas/BCAR1 Expression Is Induced by Phorbol Esters
Following the Kinetics of a Late Response Gene in
Human Breast Cancer Cells
The immediate early gene EGR1 and its coregulator, the delayed
early response gene NAB2, are highly inducible by PMA [24,31,38],
which is an activator of protein kinase C, thereby mimicking growth
factor signaling. Accordingly, depletion of growth factors leads to down-
regulation of EGR1 and NAB2, which can vary in time and strength in
different cell types. To elucidate whether BCAR1/p130Cas expression
Figure 5. Distinct binding of EGR1 to the BCAR1-1 and BCAR1-1′ 5′
regions in MCF-7 and TAM-R cells. ChIP real-time PCR was used
to investigate EGR1 binding to the BCAR1 5′ regions as described
in theMaterials andMethods. (A) Schematic of the flanking regions
of the alternative first exons of BCAR1. Positions of primers used
for ChIP analyses and putative TF binding sites within the amplified
regions are indicated. (B) Immunoprecipitated BCAR1-1, BCAR1-1′,
and negative control regions were amplified by real-time PCR as
described previously. Shown is the average relative fold EGR1
enrichment at the BCAR1 5′ regions in relation to the EGR1 binding
at the negative control DNA region (control region, set to 1) and SD
calculated from triplicate as explained in detail in the Materials and
Methods. Control region: PCR to control for chromatin bound non-
specifically. Results are from one representative experiment of at
least three performed. P values of negative control region versus
BCAR1 5′ regions, or as indicated, were calculated using t test.
*P < .05. ***P < .001. n.s. indicates not significant.
Figure 6. NAB2 expression is elevated in aggressive and late-stage
breast cancers. (A) MCF-7 and TAM-R cells were cultured similarly
for 2 weeks and seeded at 3 × 105 cells in six-well plates. After
3 days at a confluence of 70% to 90%, cells were harvested
and WCEs (20 μg) were subjected to WB to compare the basal
p130Cas, EGR1, and NAB2 protein levels. Actin was used as a load-
ing control. Results are presented from one representative ex-
periment of three performed. (B) Box plots of data from breast
carcinoma microarray data sets using the Oncomine Cancer Pro-
filing Database (www.oncomine.org) plotted on a log scale. The
t test was performed directly through the Oncomine 4.4 software.
n indicates the number of samples in each group. Left panel: a box
plot of data from the Ginestier study (reporter number 216017_s_at)
[43] including grade 2 and grade 3 human invasive ductal breast
cancer samples. The difference inNAB2mRNA expression between
the two groupswas significant (P= .023). Right panel: data from the
Radvanyi study (reporter number U48361) [45] including samples of
human breast cancer obtained from the primary site (prim.) or
metastasis (metast.). The difference in NAB2 expression between
the two groups was significant (P = .034).
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Figure 7. p130Cas mRNA and protein expression are inducible in response to phorbol esters. (A-D) MCF-7 and TAM-R cells, as indicated,
were serum starved for 16 hours followed by stimulation with PMA for indicated times up to 60 hours or left untreated (0 h). (A and B,
upper panel, and C and D) Results are presented from one experiment of three performed with similar results. (A) Upper panel: WCEs
(20 μg) were analyzed for p130Cas, EGR1, and NAB2 protein expression by WB. Lower panel: Densitometric analysis of protein expres-
sion. (B) Upper panel: expression of total BCAR1 mRNA and of BCAR1-1, BCAR1-1′, and GAPDH (control) mRNAs was determined by
RT-PCR as described previously. − DNA indicates the negative control for PCR. Lower panel: Densitometric analysis of total BCAR1
mRNA, BCAR1-1, and BCAR1-1′ expression. (C and D) Left panels: WCEs (20 μg) were analyzed for p130Cas, EGR1, and NAB2 protein
expression by WB. Right panels: Expression of total BCAR1 mRNA and of BCAR1-1, BCAR1-1′, and GAPDH (control) mRNAs was
determined by RT-PCR as described previously. + control indicates positive control for PCR; − DNA, negative control for PCR. (E)
Densitometric analysis of p130Cas protein (left panel) and total BCAR1 mRNA (right panel) expression in MCF-7 and TAM-R cells. (A and
B, lower panel, and E) Average expression levels in relation to untreated cells (set to 1) and SD from three experiments performed were
determined. Statistically significant changes compared with untreated cells are indicated: *P < .05, **P < .01, and ***P < .001. P values
were calculated using t test.
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levels can be influenced by environmental signals, an analysis of the
expression kinetics of p130Cas in response to PMA was performed in
MCF-7 and TAM-R cells. Breast cancer cells were serum starved for
16 hours followed by PMA treatment for indicated times and the
p130Cas, EGR1, and NAB2 protein expression and total BCAR1,
BCAR1-1, and BCAR1-1′ mRNA levels were monitored by WB and
RT-PCR, respectively (Figure 7). Initial treatment of MCF-7 cells
for up to 18 hours (Figure 7, A and B) showed a weak induction of
total BCAR1 (1.18-fold, not significant) and BCAR1-1 (1.3-fold, P <
.001) mRNA levels at 2 hours continuously increasing until 18 hours
(1.77-fold [P < .01] and 2.11-fold [P < .01], respectively). A delayed
up-regulation of BCAR1-1′ was observed at 4 hours (1.25-fold, P < .05)
further increasing until 18 hours (1.74-fold, P < .001). Accordingly,
major p130Cas protein induction occurred at 12 hours, which was
stable for up to 18 hours. Coinciding with the initial up-regulation of
total BCAR1 and BCAR1-1, a transient induction of EGR1 at 2 hours
and increasing levels of NAB2 protein were detected. EGR1 returned to
basal levels at 4 hours and was reinduced at 12 and 18 hours, whereas
NAB2 expression constantly increased until 18 hours. Because a strong
up-regulation of p130Cas levels was still present, at 18 hours, the time of
the PMA treatment was extended to 60 hours to elucidate the late
expression kinetics. This study included also the tamoxifen-resistant
TAM-R (Figure 7, C -E ) and ER-negative BT-20 breast cancer (not
shown) cells. In MCF-7 cells, the total BCAR1 mRNA induction re-
mained similar for up to 60 hours, whereas a continuous increase in
protein levels was observed, reaching its maximum at 36 hours (4-fold),
which was stable for up to 60 hours (Figure 7C). Whereas the induction
of BCAR1-1′ mRNA was relatively stable for 60 hours, BCAR1-1 levels
slightly declined from 24 to 60 hours. The late p130Cas protein and
mRNA expression patterns also correlated with the protein levels of
EGR1 and NAB2 in MCF-7 cells. Similar results were obtained in
BT-20 cells (not shown).
In TAM-R cells, no major changes of total p130Cas protein and
BCAR1 mRNA levels were observed (Figure 7D). Increased EGR1
expression was observed from 24 to 60 hours, whereas NAB2 levels
were induced earlier further increasing until reaching a plateau at
∼36 hours. These results indicate that p130Cas protein and mRNA
expression is inducible in response to PMA treatment in tamoxifen-
sensitive MCF-7 cells, following the kinetics of a late response gene, but
not in tamoxifen-resistant TAM-R cells (as compared in Figure 7E).
Differential p130Cas Regulation of EGR1 and NAB2
Expression in Tamoxifen-Sensitive MCF-7 and
Tamoxifen-Resistant TAM-R Cells
In response to numerous stimuli, p130Cas mediates the activation
of multiple signaling pathways including the Ras/mitogen-activated
protein kinase and PI3K/Akt cascades [5,19]. Because EGR1 expres-
sion is regulated through mitogen-activated protein kinase and PI3K-
dependent pathways [46], the influence of p130Cas on endogenous
EGR1 levels was investigated. MCF-7 and TAM-R cells were transiently
transfected with siRNAs specific for BCAR1 or a control siRNA
(Figure 8A). In MCF-7 cells depletion of p130Cas levels by 79% led
to a reduction of EGR1 and NAB2 expression of 60% (P < .001)
and 45% (P < .01), respectively. Interestingly, a comparable down-
regulation of p130Cas in TAM-R cells did not significantly reduce
EGR1 levels but decreased NAB2 expression by 50% (P < .001). This
difference was also indirectly observed in MCF-7 and TAM-R cells as
similar EGR1 levels were found in both cell lines but profoundly ele-
vated NAB2 levels in TAM-R cells (Figure 6A). This suggests that the
higher p130Cas expression in TAM-R cells correlates with increased
NAB2 levels.
In summary, these findings suggest that in MCF-7 cells p130Cas
signaling induces the expression of EGR1 and NAB2, thereby establish-
ing a positive feedback loop to activate its own expression. Importantly,
this mechanism seems to be partially altered in the tamoxifen-resistant
derivative TAM-R (as compared in Figure 8B).
Discussion
Here, we studied the regulation of p130Cas/BCAR1 expression in
mammary carcinomas. We show for the first time that p130Cas mRNA
and protein are upregulated in response to PMA treatment, mimicking
growth factor signaling. Our results indicate that, in breast cancer cells,
Figure 8. p130Cas is involved in the regulation of EGR1 and NAB2
expression. (A) MCF-7 and TAM-R cells were transfected with
BCAR1-specific siRNAs or control siRNA. Left panel: WCEs (20 μg)
were analyzed for p130Cas, EGR1, NAB2, and actin (control) expres-
sion by WB 48 hours after treatment. Results are presented from
one representative experiment of three performed. Right panel:
Densitometric analysis of p130Cas, EGR1, and NAB2 protein expres-
sion in siRNA-treated cells. Average expression levels relative to neg-
ative control (black bar, set to 100%) and SD from three experiments
performed were determined. P values were calculated using t test.
**P < .01. ***P < .001. n.s. indicates not significant. (B) Model of
the positive feedback loop regulating p130Cas expression in re-
sponse to environmental stimuli in tamoxifen-sensitive MCF-7 and
tamoxifen-resistant TAM-R breast cancer cells. Solid arrows depict
direct interactions or up-regulation/activation; dashed arrows indicate
additional undefined steps in between leading to an up-regulation of
expression. Right panel: Red color indicates enhanced activity or
expression (as shown by larger size symbols) of the depicted mole-
cule or process in TAM-R versus MCF-7 cells.
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p130Cas mediates the induction of the TF EGR1 and its coregulator
NAB2. Moreover, EGR1 and NAB2 are, in turn, involved in the
up-regulation of p130Cas/BCAR1, pointing to the existence of a positive
feedback loop in mammary cancers. Importantly, we discovered sig-
nificant differences in the p130Cas/EGR1/NAB2 network among
tamoxifen-sensitive and tamoxifen-resistant breast cancer cells. We
demonstrated that NAB2 expression is elevated in tamoxifen-resistant
breast cancer cells and in advanced and more aggressive human breast
cancers, suggesting that NAB2 contributes to the enhanced levels of
p130Cas found in these cancers.
Previously, we showed that p130Cas protein levels are elevated
in vitro in tamoxifen-resistant breast cancer cells (TAM-R) [19].
Our experiments now revealed increased BCAR1 mRNA expression
in the same tamoxifen-resistant TAM-R model system compared with
the parental tamoxifen-sensitive MCF-7 cells [19,20]. These data sug-
gest that increased expression of BCAR1 may contribute to the previ-
ously observed elevated p130Cas protein levels in tamoxifen-resistant
cells and possibly in breast cancer. Corresponding to the alternative
first exon variants Casa and Casb of murine p130
Cas that did not show
altered activity in binding to focal adhesion kinase [41], we identified
the human mRNA orthologs, referred to as BCAR1-1 and BCAR1-1′,
respectively. The large genomic distance between the first exon of
each variant supports the potential usage of alternative promoters.
The in silico analysis of the 5′ regions of both BCAR1 variants
revealed several prominent clusters of overlapping EGR/SP1 sites.
Similar cis regulatory elements present in the promoters of, for exam-
ple, the vascular endothelial growth factor (VEGF) [28], PDGF-A [29],
and NAB2 [32], have been shown to be essential for driving EGR1-
induced gene expression. With knockdown approaches and overexpres-
sion studies, we showed that EGR1 and its coregulator NAB2 control
BCAR1/p130Cas expression in breast cancer cells. The EGR1 target
NAB2 can act as both a corepressor [31,32] and a coactivator [30] of
EGR1-mediated transcription. Our studies suggest that NAB2 coacti-
vates the EGR1-mediated increase in p130Cas levels and that complex
formation of EGR1 and NAB2 may be required to positively regulate
p130Cas expression. More potent NAB2 regulatory effects on BCAR1/
p130Cas and EGR1 levels in TAM-R versus MCF-7 cells were revealed
by NAB2 knockdown experiments. In MCF-7 cells, NAB2 depletion
primarily affected BCAR1-1′ levels, whereas in TAM-R cells, BCAR1-1,
BCAR1-1′ mRNAs, and EGR1 mRNA and protein were significantly
reduced. This suggests that NAB2 is important for BCAR1-1′ expres-
sion in both cell lines and, in addition, in TAM-R cells for maintaining
EGR1 and BCAR1-1 levels. Importantly, higher basal NAB2 expres-
sion was found in TAM-R versus MCF-7 cells, and consistently, in
ChIP assays performed with these cell lines, significantly increased
binding of EGR1 to the BCAR1 5′ regions in TAM-R cells was
observed. Therefore, our studies suggest that high constitutive NAB2
levels may result in sustained EGR1/NAB2 complex formation impor-
tant for the recruitment of EGR1 to the BCAR1 regulatory 5′ regions
and subsequently enhanced BCAR1/p130Cas levels in tamoxifen-
resistant TAM-R cells. Correspondingly, elevated total BCAR1mRNA
levels and a similar increase in the expression of both exon 1 variants
were found in TAM-R cells in comparison toMCF-7 cells (Figure 1, C
and D). This suggests that, in this tamoxifen-resistant model, both
BCAR1 variants are regulated by likewise mechanisms. However, the
different expression patterns of the two mRNA variants in additional
breast tissues and a breast cancer cell line (Figure 1C ) suggest that
additional mechanisms may distinctly regulate the expression of the
two p130Cas isoforms by, for example, tissue-specific TFs or in response
to different signaling pathways altered during tumor development/
progression. Such mechanisms have been observed for the aromatase
(Cyp19) [47] and ERα genes (ESR1) [48]. Because increased NAB2
expression was also found in breast cancer specimens derived from
higher-grade tumors and metastases [43–45], this mechanism may
contribute not only to the elevated BCAR1/p130Cas levels observed
in tamoxifen-resistant but also in aggressive/advanced mammary
carcinomas [14,15,40].
Binding sites for members of additional TF families, such as NF-κB,
p53, and HIF, that are inducible or activated by multiple signaling
pathways, were predicted in the 5′ regions of the alternative first
BCAR1 exons by in silico analysis. At this point, their importance in
BCAR1 regulation cannot be ruled out, and these sites further point
to the inducibility of p130Cas/BCAR1 expression. However, p130Cas/
BCAR1 levels have not yet been linked to cell cycle progression or to be
upregulated by extracellular stimuli such as growth factors as it is
known for the family member HEF1 [7]. Previous studies primarily
focused on the early posttranslational modifications of the p130Cas
protein in response to different stimuli. Our comprehensive investiga-
tion of the expression kinetics in response to phorbol esters, mimicking
growth factor signaling, indicated for the first time that p130Cas protein
and BCAR1 mRNA are inducible following the kinetics of a late re-
sponse gene in MCF-7 cells. However, BCAR1/p130Cas levels were
not majorly influenced in TAM-R cells, which may in part be explained
by the high basal BCAR1/p130Cas expression in these cells. In addition,
this implies that the elevated BCAR1/p130Cas levels in TAM-R cells
might be maintained by intrinsic mechanisms. These altered activities
in MCF-7 and TAM-R suggest changes in the regulation of BCAR1
expression during acquired tamoxifen resistance.
In summary, based on the results presented here, we propose the
following models for the regulation of BCAR1 expression in tamoxifen-
sensitive and -resistant cells (Figure 8B). In the tamoxifen-sensitive
MCF-7 cells, upon extracellular stimuli, p130Cas is activated/phosphorylated,
leading to the activation of downstream signaling pathways [7] that
induce the expression of the immediate early gene EGR1 [46]. Subse-
quently, EGR1 activates the transcription of the delayed early response
gene NAB2 [33]. In turn, the EGR1/NAB2 complex mediates the late
induction of BCAR1, thereby establishing a positive feedback loop. In
contrast, in the tamoxifen-resistant TAM-R cells, p130Cas levels are not
majorly influenced by phorbol esters, mimicking growth factor signal-
ing. Therefore, we suggest that the constitutively high expression and
phosphorylation levels of p130Cas [19] lead to enhanced downstream
signaling and possibly to a constant induction of NAB2. Because
p130Cas signaling does not influence EGR1 levels in TAM-R cells,
other TFs of, for example, the EGR family [32] may induce NAB2 ex-
pression. High NAB2 expression is important for maintaining basal
EGR1 levels in these cells and, subsequently, results in enhanced
EGR1/NAB2 complex formation and thus the activation of BCAR1
expression. This reciprocal circuit may in part explain why p130Cas and
NAB2 expression is constitutively upregulated in TAM-R cells.
The results of our studies in identifying EGR1 and NAB2 as regu-
lators of p130Cas/BCAR1may have an impact not only on breast cancer
but also on other malignancies. Recently, p130Cas/BCAR1 was identi-
fied as a key player in prostate carcinomas, and increased levels were
associated with aggressiveness and progression of this disease [49,50].
Because EGR1 overexpression has been described in multiple studies
to be crucial for driving prostate cancer progression [51–53], it may also
contribute to the up-regulation of p130Cas in this type of cancer. It
would be interesting to see whether the p130Cas/EGR1/NAB2 circuit
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or alterations of this network may play a role in promoting these
carcinomas as well.
Further deciphering of the precise mechanism of the p130Cas/
EGR1/NAB2 feedback loop may help to understand the molecular
biology not only of breast cancers but also of other malignancies and to
identify new targets for the development of novel treatment strategies.
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